An inhalation reference concentration (RfC) was developed for diethanolamine (DEA), based principally on evaluation of three animal studies (Gamer et al., 1993 (Gamer et al., , 1996 (Gamer et al., , 2008 . The RfC (25 μg/m 3 ) was based on statistically significantly increased relative liver weight in female rats in Gamer et al. (2008) as the critical effect. The lower confidence limit on the benchmark dose (BMDL 10 of 5.5 mg/m 3 ) was adjusted to a human equivalent concentration and to continuous exposure before dividing the final point of departure (2.3 mg/m 3 ) by a total factor of 90 that considered standard key areas of uncertainty (intrahuman variability, potential interspecies toxicodynamic differences, database limitations). While laryngeal effects observed in Gamer et al. (2008) were also considered as candidate critical effects, evaluation of the adversity and human relevance of rat laryngeal squamous metaplasia and concomitant effects at the various exposure levels resulted in identifying a LOAEL for laryngeal squamous hyperplasia and chronic inflammation that was much higher than the liver weight LOAEL identified. The RfC of 25 μg/m 3 is considered health protective for the general population and can be used to evaluate the potential health effects of long-term environmental exposure of the general public (i.e., long-term, ambient air dispersion modelling or monitoring data).
Introduction
Ethanolamines have been of steadily growing commercial importance as chemical intermediates since the 1940's because of the large-scale production of ethylene oxide, with the economical production of very pure ethanolamines being possible since the 1970's (IARC, 2000) . Annual world-wide capacity for ethanolamines was estimated at 1.5 million tons (for 2005), with more than half attributable to North and South America, including multiple facilities in the United States (US) (OECD, 2007; IARC, 2013) . Diethanolamine (DEA) is produced by reacting ethylene oxide with ammonia in a batch process that yields a mixture of monoethanolamine (MEA), DEA, and triethanolamine (TEA). Individual compounds can then be separated and purified by distilling this mixture (Edens and Lochary, 2004) .
DEA is used widely in the production of diethanolamides and diethanolamine salts of long-chain fatty acids that are formulated into soaps and surfactants used in liquid laundry and dishwashing detergents, cosmetics, shampoos, and hair conditioners. It is also used in the production of lubricants in the textile industry, in industrial gas purification, as an emulsifier and dispersing agent in agricultural chemical preparations, in metalworking fluids and die-casting operations as a corrosion inhibitor and antimicrobial agent, and as a chemical intermediate in the manufacture of resins and plasticizers. Hair products such as shampoos and dyes may contain DEA as a component and/or a contaminant of fatty acid alkanolamides in the range of ≈0.1-10% (Bailey, 2007; IARC, 2013; ACGIH, 2009 ). Major use estimates of DEA in the US are: surfactants (39%), gas purification (30%), textile processing (15%), metalworking fluids (10%), laundry detergents (2%), and agricultural chemicals (2%) (Knaak et al., 1997) . The US Food & Drug Administration (USFDA) allows DEA for various uses (e.g., as a component of certain food packaging products) and as an indirect food additive (IARC, 2013; ACGIH, 2009) .
DEA is not monitored in ambient air by the Texas Commission on Environmental Quality's (TCEQ) monitoring program because standard analytical methods cannot measure all chemicals. However, it is important for the TCEQ to derive a chronic inhalation toxicity factor (e.g., reference concentration or RfC, termed a chronic reference value or ReV in Texas) for DEA for several reasons:
• Although a recent scientific literature search identified chronic inhalation toxicity factors derived by other agencies for use in the protection of public health (i.e., OEHHA, 2001; USEPA, 2012) , those toxicity factors are based on an endpoint (i.e., laryngeal lesions in rats) for which critical recent guidance and information regarding adversity is now available but was not considered in the dose-response assessments (e.g., Mowat et al., 2017; Kaufmann et al., 2009;  https://doi.org/10.1016/j.yrtph.2017.11.011 Received 21 June 2017; Received in revised form 14 November 2017; Accepted 16 November 2017
• Most importantly, DEA is emitted by various facilities in Texas (i.e., per the emission limits contained in their respective air permits based on air dispersion modelling of off-site, ground-level concentrations), and therefore the derivation of an RfC will help ensure the protection of public health.
Because of the comprehensiveness of the language in the THSC, the TCEQ develops inhalation toxicity factors (e.g., ReVs, unit risk factors) for as many air contaminants as possible, even for chemicals with toxicity data more limited than that which would be required by other agencies' programs that conduct hazard identification and dose-response assessment (e.g., the US Environmental Protection Agency's (USEPA's) Integrated Risk Information System program). The development of scientifically-defensible inhalation toxicity factors under the TCEQ toxicity factor guidelines (TCEQ, 2015) includes the consideration of the standard key uncertainties associated with extrapolating laboratory animal data to humans (e.g., potential interspecies toxicodynamic differences, database limitations), and is consistent with TCEQ's goal of protecting human health and the environment. The purpose of this paper is to document the derivation of an RfC for DEA (referred to as a chronic ReV in TCEQ, 2015) , which may be used in the protection of public health (e.g., in the TCEQ air permitting process).
Materials and methods
The TCEQ guidelines (TCEQ, 2015) employ the 4-stage risk assessment process formalized by the National Research Council (NRC, 1983 (NRC, , 1994 and procedures recommended in numerous USEPA risk assessment guidance documents and the scientific literature (e.g., USEPA, 1994 USEPA, , 2002 . Briefly, the basic steps of our toxicity factor derivation include:
(1) Reviewing essential data (e.g., physical/chemical properties) and searching the literature to identify potential key studies (e.g., those with a dose-response and the most conservative lowest-observedadverse-effect-levels (LOAELs) and no-observed-adverse-effect-levels (NOAELs)); (2) Considering mode of action (MOA) data relevant to appropriate low-dose extrapolation procedures (e.g., threshold non-carcinogenic responses versus linear low-dose extrapolation when conducting a carcinogenic dose-response assessment for chemicals with a mutagenic carcinogenic MOA); (3) Selecting the best available dose metric (frequently air concentration for inhalation studies); (4) Conducting appropriate dosimetric modelling (e.g., animal-tohuman) to produce human equivalent concentrations (HECs) for points-of-departure (PODs) that potentially identify the critical adverse effect (e.g., relatively low study LOAELs), as well as exposure regimen/duration adjustments; (5) Identifying the critical adverse effect based on the lowest HEC for an adverse, human-relevant effect (e.g., the lowest HEC based on a study LOAEL (LOAEL HEC ) may be used); and (6) Extrapolating from the most appropriate POD HEC for the critical effect (e.g., a POD HEC corresponding to the BMDL 10-HEC ) to lower exposures, which for chronic non-carcinogenic effects typically entails dividing the duration-adjusted POD HEC by applicable uncertainty factors (TCEQ, 2015).
For non-carcinogenic effects, consistent with standard methods used for toxicity factor derivation by other agencies (e.g., USEPA, ATSDR), the central elements of this process entail identifying the POD HEC for the critical adverse effect and dividing it by appropriate safety factors that consider relevant key areas of uncertainty (e.g., intrahuman variability, potential interspecies differences in toxicodynamics, database limitations) [see TCEQ 2015 for more detailed information]. The focus of this manuscript is to document these key elements with the associated methods and rationale for a DEA RfC derivation, based on a critical toxicological evaluation of the results reported in three animal inhalation studies by Gamer et al. (1993 Gamer et al. ( , 1996 Gamer et al. ( , 2008 as well as other relevant information (e.g., criteria relevant to endpoint adversity, TCEQ guidance, developmental/reproductive toxicity results for other exposure routes). Additional details are provided in the sections that follow.
Identification and discussion of key studies
A scientific literature search was conducted for DEA to identify relevant studies via online databases (i.e., PubMed, Toxline, Hazardous Substances Data Bank, Registry of Toxic Effects of Chemical Substances, Screening Information Datasets for High Volume Chemicals). For example, the initial PubMed search for "diethanolamine" (June 2016) yielded approximately 500 articles simply related to DEA in some regard. Review of the abstracts resulted in the exclusion of studies that were not relevant for a chronic RfC dose-response assessment of the potential toxic effects of DEA inhalation (e.g., those involving chemical synthesis). Exclusion criteria (for purposes of dose-response assessment and toxicity factor derivation) included:
• Studies that did not assess health effects;
• Unpublished studies that were unavailable (only abstract available);
• Reports not in English;
• Lack of exposure data or original data (e.g., while review articles were examined to gain familiarity with previous assessments, they often do not contain the actual dose-response data required for derivation of toxicity factors);
• Irrelevant exposure route (e.g., intraperitoneal); • Mixture studies (i.e., wherein any effects observed are not attributable specifically to DEA); and
• Endpoints (e.g., severe effects like mortality) and exposure durations irrelevant for RfC derivation (e.g., acute, < 24-h exposure studies).
Upon review of the abstracts, however, the vast majority of the studies initially identified for DEA did not concern inhalation exposure (e.g., chemical synthesis papers). Furthermore, only three studies were identified with inhalation dose-response data relevant to derivation of an RfC. While human studies are preferred for RfC derivation under the TCEQ (2015) guidelines, as noted elsewhere (e.g., IARC, 2013) and confirmed by our updated scientific literature search, no human data are available from which to assess the potential for long-term, noncarcinogenic toxic effects attributable to DEA inhalation. In fact, use of the exclusion criteria narrowed down the number of potentially relevant studies for RfC derivation to three animal inhalation studies by Gamer et al.: two subchronic studies (Gamer et al., 1996 (Gamer et al., , 2008 ) and a 10-day gestational exposure study (Gamer et al., 1993) . The studies used two different strains of Wistar rats: Chbb:THOM was used in Gamer et al. (1993 Gamer et al. ( , 1996 and the Study 1 portion of Gamer et al. (2008) , while the CrlGlxBrIHan:WI strain was used in the Study 2 portion of Gamer et al. (2008 Gamer et al. ( , 1993 is relevant for RfC derivation as it evaluated developmental/reproductive effects following subacute gestational exposure and an RfC should be protective against these potential effects. However, as described in Sections 3.2 and 4, ultimately Gamer et al. (1993) was not chosen as the key study to derive the DEA RfC because it did not identify the critical effect (i.e., it did not identify the adverse effect that occurred at the lowest LOAEL HEC ). Both of the subchronic studies (Gamer et al., 1996 (Gamer et al., , 2008 report data relevant to the evaluation of candidate critical endpoints (i.e., laryngeal and liver effects). However, Gamer et al. (1996) used higher concentrations while Gamer et al. (2008) also used low exposure concentrations and reported additional information (i.e., laryngeal inflammatory cell infiltration and liver weight data at lower concentrations) from which a more full evaluation of potential critical effects can be made and a reliable LOAEL and NOAEL can be identified for the critical effect. Consequently, the primary subchronic animal study used for RfC derivation is Gamer et al. (2008) .
3.1. Gamer et al. (2008) This key study was conducted in accordance with Organisation for Economic Co-operation and Development (OECD), European Union (EU), USEPA, and Good Laboratory Practice (GLP) guidelines (e.g., OECD, 1981a,b; EEC, 1988; USEPA, 1985 USEPA, , 1987 USEPA, , 1998 . For the subchronic portion of the study (conducted following the subacute dosefinding study), Wistar rats were exposed nose-only to either DEA or TEA. For purposes of this DEA assessment, study TEA exposures and associated results will not be discussed. There were two subchronic DEA studies conducted at different target exposure concentrations:
• Study 1 -In this higher-concentration study, groups of male and female rats (13/sex/group; purchased at 7 weeks of age, exposure age unknown) were exposed to target DEA concentrations of 0, 15, 150, and 400 mg/m 3 for 6 h/day for 65 days over a 99-day period (animals were exposed every workday except for the days during which functional observational battery (FOB) tests were performed).
• Study 2 -For this lower-concentration study, groups of male and female rats (10/sex/group; purchased at 7 weeks of age, exposure age unknown) were exposed to target DEA concentrations of 0, 1.5, 3, and 8 mg/m 3 for 6 h/day for 65 days over a 99-day period (but without FOB tests), and additional groups of female rats (10/group) exposed to 3 or 8 mg/m 3 were allowed to recover for 3 months postexposure.
Both studies included control groups (0 mg/m 3 ) with the respective numbers of animals/sex exposed to clean air. Clinical examinations included observations for overt toxicity, body weights, ophthalmoscopy, and comprehensive neurofunctional tests (Study 1) using an FOB. The FOB consisted of various parameters of sensory and motor functions such as reflex and sensorimotor tests covering responses to visual, auditory, olfactory, and touch stimuli (e.g., pupillary reflex, startle response, blinking reflex), neuromotor alterations (e.g., pain perception, grip strength), and motor activity tests. Animals also underwent extensive clinical chemistry and histopathological analysis, including a histopathology investigation of the respiratory tract (e.g., nasal cavity, larynx, trachea with bifurcation), hematology, urinalysis, gross pathology, and comprehensive neuropathological examination (see Sections 2.7-2.9 of Gamer et al., 2008 for additional details). For Study 1, actual measured concentrations for the DEA-exposed groups were 15.2 ± 2.3, 153 ± 20, and 410 ± 45 mg/m 3 . For Study 2, measured concentrations for the exposed groups were 1.6 ± 0.3, 3.3 ± 0.8, and 8.2 ± 1.5 mg/m 3 . The mass median aerodynamic diameter (MMAD) was 0.6-1.9 μm for Study 1, and was smaller and less variable for Study 2 at 0.6-0.7 μm. Geometrical standard deviations (GSDs) were reported to range from 2 to 3.
Study 1 (high-concentration) results and discussion
No deaths occurred in any of the exposure groups. Clinical examination revealed a substance-related, statistically significant (p < 0.01) decrease in body weight of male rats in the 410 mg/m 3 exposure group (see Table 2 of Gamer et al., 2008) . Additionally, several changes in clinical pathological parameters were observed in the 410 mg/m 3 exposure group, including statistically significant (p < 0.01 or 0.05) decreases in red blood cells, hemoglobin, hematocrit, and mean corpuscular volume in male and female animals (see Table 4 Table 2 of Gamer et al., 2008) . At 153 and 410 mg/m 3 , histopathological examination of the kidneys showed minimal/slight tubular hyperplasia in some females and slightly pronounced intratubular lithiasis in some males. Gamer et al. (2008) viewed these results as consistent with the liver and kidney toxicity evident from lower oral doses of DEA. From this, they concluded that DEA induced mild systemic toxicity on the blood, liver, and kidney at target exposure concentrations ≥150 mg/m 3 . Gross lesions (i.e., erosions) on the stomach epithelium were also observed in females exposed to 153 and 410 mg/m 3 . All exposed animals (100% incidence, down to 15.2 mg/m 3 ) showed focal squamous metaplasia of the ventral laryngeal epithelium at the base of the epiglottitis (level 1), with the 153 and 410 mg/m 3 exposure groups showing increases in laryngeal squamous hyperplasia as well as increases in incidence and severity of local inflammation in the larynx (see Table 1 , which contains data derived from Table 5 of Gamer et al., 2008) .
Study 2 (low-concentration) results and discussion
No substance-related clinical signs, body weight changes, or neurological signs were noted in any of the exposure groups. Reflecting a similar pattern of response as in Study 1, a statistically significant (p < 0.05) increase in relative liver weight was observed in females exposed to 8.2 mg/m 3 in this study. However, the increase in relative liver weight observed in females at 15.2 mg/m 3 in Study 1 did not achieve statistical significance, unlike females exposed to 153 and 410 mg/m 3 (see Table 2 , which contains data derived from Table 2 of Gamer et al., 2008) . Gamer et al. (2008) attribute this difference in statistically significant responses for increased relative liver weight to, "the variability of different populations of animals used in independent studies." That is, the studies used two different rat strains (Chbb:THOM versus CrlGlxBrIHan:WI) from different vendors. To this point, although the rats were reported to be purchased at about 7 weeks of age, we note that no mention was made about the age of the rats at exposure, and the rats in the lower-concentration study (Study 2) had appreciably lower body weights (initial control animal mean body weights of 225 g (male) and 167 g (female) for Study 2 versus 280 g (male) and 200 g (female) for Study 1). Furthermore, the Study 2 animals were exposed to particles with an appreciably smaller and less variable MMAD (0.6-0.7 μm in Study 2 versus 0.6-1.9 μm for Study 1), which is predicted to have increased pulmonary deposition and thereby likely increased systemic dose. For example, using the midpoints of the MMAD ranges ( were set at default values). Adjusting study exposure concentrations by different deposition fractions modelled for the two studies produces doses that are more similar between the higher-(Study 1) and lowerconcentration studies (Table 2 ). This adjustment reduces the difference in the doses associated with statistically increased relative liver weight between the two studies to approximately an order of magnitude (i.e., comparing the doses induced by exposure to 150 mg/m 3 versus 8 mg/ m 3 DEA). However, the difference in modelled deposition fraction may only partially explain the difference in response in the higher-and lower-concentration studies, with some of the difference also likely attributable to variability of different animal populations in independent studies as noted by the study authors. Thus, for several reasons the results from the two studies are not entirely comparable, which may explain the statistically increased relative liver weight at 8.2 mg/m 3 in Study 2 but not at 15.2 mg/m 3 in Study 1.
Different rat strains, control data, and MMAD ranges preclude combining data from the two studies into one dataset for use in benchmark dose (BMD) modelling or statistical testing for trends across all study exposure groups. In regard to pairwise comparisons, there was no statistical difference between the female rat relative liver weight in the control group compared to the 1. 6 (Table 2 ).
Overall these statistical results are consistent with increased relative liver weight across groups of female rats exposed to DEA. We consider 8.2 mg/m 3 as the LOAEL for statistically significant (p < 0.05) and biologically significant (> 10%) increased relative liver weight under the exposure conditions (i.e., smaller MMAD range combined with lower concentrations) and for the strain of female rats (CrlGlxBrIHan:WI) used in the low-dose study (see Table 3 ). Gamer et al. (2008) considered 150 mg/m 3 to be the study LOAEL for liver effects. By comparison, Hartung et al. (1970, only abstract available) reported increased liver weight and serum glutamate oxaloacetate transferase (an indicator of liver damage) in male rats exposed continuously to a lower concentration (108 mg/m 3 ) after only 9 days. Additionally, consistent with our assessment, USEPA (2012) considered the liver weight changes observed in the low-dose study as a candidate critical effect for RfC derivation. Based on consideration of the factors discussed above and a 14% increase in relative liver weight, which is considered adverse for a putative target organ under our guidelines (i.e., > 10% increase), we conservatively consider 8.2 mg/ m 3 to be the subchronic LOAEL and 3.3 mg/m 3 to be the clear NOAEL for liver effects (in female rats) based on our evaluation of study results. Effects similar to those observed in the larynx of Study 1 animals exposed to 15.2 mg/m 3 were also observed in the 8.2 mg/m 3 exposure group of Study 2. Male and female rats exposed to 8.2 mg/m 3 showed focal squamous metaplasia of the laryngeal epithelium, with a 90% incidence at level 1 (at the base of the epiglottis) in both sexes and a 20% incidence at level 2 (at the region of the ventral pouch and arytenoid cartilages) in males only (see Table 1 ). Inflammatory cell infiltration was also slightly increased over controls (5/20 across grades at 8.2 mg/m 3 versus 3/20 in controls; as in Table 5 of Gamer et al., 2008, control incidence is not shown in Table 1 here but discussed in Table 5 of Gamer et al. (2008) ; blank fields imply no findings.
b Incidence values shown are male/female with n = 10/sex (e.g., 0/3 = 0/10 males and 3/10 females with effect). c Control animal incidences were 1/1 (10% incidence in each sex). d Controls animal incidences were 1/0 (10% incidence in males). text). Focal squamous metaplasia (level 1) was also noted in 3/10 male rats in the 3.3 mg/m 3 exposure group, which had less epithelial inflammatory cell infiltration (0%) than even that observed in the controls (3/20 or 15%). The remaining respiratory tract (and the respiratory tracts of the recovery animals) showed no histopathological changes. All lesions in the larynx were reversible within 3 months after the end of exposure. Gamer et al. (2008) identified 3.3 mg/m 3 as the study NOAEL since they considered the laryngeal squamous metaplasia observed at this concentration, but not that observed at any higher concentrations, to be adaptive in character based on their interpretation and application of guidance in a recent expert pathologist workshop publication (Kaufmann et al., 2009) . Although not explicitly identified as such, by corollary Gamer et al. (2008) considered 8.2 mg/m 3 to be the study LOAEL based on the co-occurrence of laryngeal squamous metaplasia with slightly increased inflammatory cell infiltration. This conclusion was based on consideration of guidance provided in Kaufmann et al. (2009) on assessing the adversity/non-adversity of squamous metaplasia of the larynx occurring both alone and when concomitant with other effects. However, based on careful review of the Gamer et al. (2008) results in the context of Kaufmann et al. (2009) should not be considered a LOAEL for effects in the rat larynx (see the following section). Thus, we consider 8.2 mg/m 3 to be the conservative study LOAEL for liver effects in female rats (with an associated NOAEL of 3.3 mg/m 3 ) but not for laryngeal effects in rats.
3.1.3. Critical evaluation of squamous metaplasia and inflammatory cells observed in the rat larynx in Gamer et al. (2008) Metaplasia is defined by pathology textbooks as an adaptive and potentially reversible change in which one mature cell type is replaced by another mature cell type (Kumar et al., 2005) . More specifically, squamous metaplasia is a term describing the replacement of normal respiratory epithelium by stratified squamous epithelium and usually involves only the superficial epithelium, but may extend into the seromucinous laryngeal glands. There is no evidence that this lesion predisposes to malignancy and no treatment is recommended (Ferlito et al., 2012) . Laryngeal squamous metaplasia is frequently reported in short-and long-term rodent inhalation studies (≈30-40%), with use of the term encompassing a wide range of different stages of laryngeal epithelial cell alterations (e.g., minimal/focal up to severe/diffuse). Use of this general term to describe a wide range of response severities results in the potential for misinterpreting the adversity of the response in a particular instance (Kaufmann et al., 2009) . Consequently, an international expert workshop was held and an associated paper published (Kaufmann et al., 2009 ) to provide guidance for classifying rodent laryngeal lesions as to adversity (i.e., adverse, non-adverse, precancerous).
As described in Kaufmann et al. (2009) , absent the co-occurrence of more clearly adverse effects, squamous metaplasia of the rat larynx that is not characterized as at least moderate to severe should be considered adaptive and non-adverse (i.e., moderate/severe = assumption of potential dysfunction and adversity, while minimal/slight = non-adverse absent other concomitant adverse effects). The adaptive and non-adverse nature of mild laryngeal squamous metaplasia is supported by other scholarly works, its well-differentiated character, the lack of significant clinical observations or progression over time, and human data indicating that squamous metaplasia of the larynx occurs in at least 50% of healthy, non-smoking men and women, irrespective of age or residence (rural versus urban) (Osimitz et al., 2007; Stell et al., 1982a,b) . Moreover, squamous metaplasia is common even in the subglottic (lower larynx) region of the non-smoking population, is common in the human fetal larynx, and no treatment is recommended when it is observed in clinical situations (Ferlito et al., 2012) . Moderate to severe squamous metaplasia, however, is viewed by Kaufmann et al. (2009) as consistent with a potential for dysfunction of the larynx, while minimal/slight laryngeal squamous metaplasia is not expected to result in dysfunction. This is consistent with how Gamer et al. (2008) applied the considerations in Kaufmann et al. to their study results, relying on the co-occurrence of laryngeal squamous metaplasia and inflammatory cell infiltration in how they defined adversity since they could not exclusively rely on the diffuse (i.e., level 1 and 2) minimal metaplasia that occurred in males at 8.2 mg/m 3 (see Figs. 8 and 9 of Gamer et al., 2008 and Table 1 of the current study). However, we interpret the laryngeal rat data of Gamer et al. (2008) differently as to adversity based on Kaufmann et al. (2009) and other toxicological considerations. Kaufmann et al. (2009) indicate that additional laryngeal findings such as inflammatory lesions have to be taken into account when assessing the adversity of metaplasia, as an increased inflammatory reaction (e.g., submucosal inflammation) is frequently detected in affected animals and inflammatory responses are regarded as adverse. For this reason, Gamer et al. (2008) suggest that the co-occurrence of laryngeal metaplasia with a slightly increased occurrence of inflammatory cells is adverse. However, this raises the question as to whether the apparent slight increase in the presence of inflammatory cells (5/20 at 8.2 mg/m 3 versus 3/20 in controls; control incidence provided here but not shown in Table 1 ) is sufficient when combined with minimal laryngeal metaplasia to give rise to an indication or expectation of functional impairment. Alternatively, it may merely mark the beginning of a process that could ultimately lead to inflammation that may produce functional impairment/dysfunction, but falls short of adversity itself. We suggest the latter. As opposed to a more clearly adverse frank effect like chronic inflammation, the mere presence of inflammatory cells at an incidence just above that for controls is not itself adverse (e.g., no functional impairment). The co-occurrence of minimal laryngeal metaplasia does not change this, as this adaptive response would neither be expected to result in functional impairment (i.e., dysfunction of the larynx) nor reduce an organism's ability to respond to an additional environmental challenge (in fact, it is replacing a more sensitive cell type with one more resistant to environmental challenge; Kaufmann et al., 2009 ). Thus, these two non-adverse effects occurring at the same lowest-observed-effect-level (LOEL) do not amount to an adverse effect (i.e., LOEL + LOEL ≠ LOAEL). Further, an August 2015 USFDA presentation on Challenges in Nonclinical Development of Inhalation Drug Products (USFDA, 2015) presents example rat laryngeal squamous metaplasia data very similar Gamer et al. (2008) .
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Regulatory Toxicology and Pharmacology 92 (2018) [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] to those in Gamer et al. (2008) . The USFDA example data are provided in Table 4 . Laryngeal squamous metaplasia is shown by USFDA at a 100% incidence with a 20% (4/20) incidence of polymorphonuclear cell infiltration (a constant feature of acute inflammation) at the middose. By contrast, bronchiolar inflammation and other effects (e.g., bronchial epithelial hyperplasia) are shown to have occurred at the high-dose. Similarly, Gamer et al. (2008) data show a 90% incidence of laryngeal metaplasia (level 1) and an approximate 20% incidence of inflammatory cell infiltration (although also present in some control animals) at 8.2 mg/m 3 (Table 1) . Moreover, essentially identical to the example USFDA data, Gamer et al. (2008) data show a 100% incidence of laryngeal metaplasia and a 20% incidence of inflammatory cell infiltration at 15.2 mg/m 3 . The USFDA presentation, however, identifies the mid-dose as the NOAEL, which is inconsistent with the Gamer et al. (2008) evaluation, but is consistent with our evaluation of the findings (e.g., 8.2 mg/m 3 is not the LOAEL based on laryngeal effects).
Moreover, multiple groups have expressed the opinion that laryngeal squamous metaplasia is not a relevant endpoint to use in extrapolating risk of inhalation exposure from rodents to humans. The USFDA presentation refers to rat laryngeal squamous metaplasia as a species-specific response, consistent with regulatory authorities that usually accept typical laryngeal changes in the rat as being non-specific and generally not relevant to humans for pharmaceutical registration (Mowat et al., 2017) . Additionally, in an American College of Toxicology annual meeting symposium summary paper (Tepper et al., 2016) , Dr. Luqi Pei of USFDA writes, "Inhalation toxicology studies may produce species-specific findings that are not relevant to humans. Laryngeal squamous metaplasia in rodents is one example." Relative to humans, the rodent larynx and carina have greater susceptibility, which emphasizes their lack of relevance for man (Mowat et al., 2017) . Similarly, Osimitz et al. (2007) conclude that squamous metaplasia of the rodent larynx is not a relevant toxicologic endpoint. This review of relevant data by USFDA and others further supports that 8.2 mg/m 3 should not be considered a LOAEL based on laryngeal effects. Kaufmann et al. (2009) further indicates that some other histopathological changes (e.g., atypia, dysplasia, dyskeratinization) should also be considered when assessing adversity, including focal squamous hyperplasia. Squamous cell hyperplasia is a change in which the epithelium becomes thicker (without cellular atypia) due to an increase in the prickle cell (acanthosis) and/or basal cell layers. It is a reversible change not considered itself to carry premalignant potential, unlike some other laryngeal changes (e.g., dyskeratosis, laryngeal intraepithelial neoplasia, atypia, dysplasia) (Ferlito et al., 2012) , although for carcinogens it is associated with the progression of effects leading to neoplasia (Kaufmann et al., 2009 Table 3 .
Gamer et al. (1993)
An RfC should also consider and be protective of potential developmental and reproductive effects (TCEQ, 2015) . Briefly, in an OECDcompliant prenatal study, Gamer et al. (1993) exposed groups of 25 pregnant Wistar rats (strain Chbb:THOM, nose-only exposure) to target DEA concentrations of 0, 10, 50, and 200 mg/m 3 for 6 h/day on gestational days (GD) 6-15. Gamer et al. (1993) indicate that the strain used (SPF-Wistar/Chbb:THOM) is sensitive to teratogenic substances. Analytical concentrations for DEA-exposed groups were 10, 50, and 202 mg/m 3 , with an MMAD < 1.2 μm and GSD of 4.1-6.3. Dams were examined for various clinical signs and findings (e.g., body weight changes, behavior, state of health), and at termination for gross pathology and uterus and ovary data (e.g., uterus weight, number of corpora lutea), including the number/distribution of implantation sites for live fetuses and dead implantations (i.e., early and late resorptions, dead fetuses). Conception rates were also calculated. Fetuses underwent numerous examinations such as: weight; sex (e.g., for sex distribution analysis); external findings; condition of the placentae, umbilical cords, fetal membranes and fluids; placental weight; and organ and skeletal examinations for malformations (e.g., exencephaly, atresia ani, hernia umbilicalis), variations (e.g., dilated renal pelvis), retardations (e.g., delays in sternebrae ossification), and other observations. There were no DEA-related maternal body weight changes, findings at necropsy, or reproductive effects (e.g., conception rate or number of corpora lutea, implantation sites, pre-and post-implantation losses, resorptions, or the viability of fetuses). Maternal toxicity, indicated by vaginal hemorrhage in 8 of the dams on GD 14, was observed at 202 mg/m 3 . Fetotoxicity, evidenced by a statistically significant (p < 0.05) increased incidence of total fetal skeletal variations (i.e., an increase in the number of cervical ribs), was also observed at 202 mg/ m 3 . Based on the scientific literature, the study authors considered this an embryotoxic effect; a manifestation of a non-specific stress on the dams and not a teratogenic effect. Thus, while 202 mg/m 3 was the LOAEL, 50 mg/m 3 was the NOAEL for both maternal toxicity and embryo-fetal effects.
Identification of the critical adverse effect
In the practice of regulatory dose-response assessment, the critical effect is most often identified as the first adverse, human-relevant effect that occurs in the most sensitive relevant species as the dose rate of an agent increases (TCEQ, 2015) . In other words, the critical effect is the adverse effect at the lowest LOAEL or other POD associated with the occurrence of an adverse effect (e.g., BMD 10 where applicable). NOAELs are generally not used to identify critical effects since they cannot reliably identify the first adverse effect as dose rate increases (e.g., NOAELs may even be free-standing and not associated with a LOAEL for a given effect). Consequently, in the present case the critical male/female 0/0 2/6 (mean severity = 1) 10/10 (mean severity = 1.5) 10/10 (mean severity = 2) Inflammatory Cell Infiltration male/female 0/0 3/0 (mean severity = 1) 4/0 (mean severity = 1) 10/10 (mean severity = 1) Increased Alveolar Macrophage male/female 2/3 (mean severity = 1) 4/4 (mean severity = 1.1) 6/7 (mean severity = 1.2) 10/10 (mean severity = 1.4) Bronchiolar Inflammation male/female 0/0 0/0 0/0 6/5 (mean severity = 1.5) Bronchial Epithelial Hyperplasia male/female 0/0 0/0 0/0 3/1 (mean severity = 1.2) a n = 10/sex (male/female) (e.g., 2/6 = 2/10 males and 6/10 females with effect). b Identified in USFDA (2015) as the NOAEL. c Identified in USFDA (2015) as a species-specific response.
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Regulatory Toxicology and Pharmacology 92 (2018) [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] effect is determined based on the HEC corresponding to the lowest LOAEL HEC for an adverse effect. When utilizing laboratory animal data, this determination requires the interspecies extrapolation of concentrations (e.g., LOAELs) corresponding to candidate critical effects, particularly when candidate critical effects include both systemic and portal of entry (POE) effects since the extrapolation methods differ. The two candidate critical adverse effects based on Gamer et al. (2008) are increased relative liver weight in female rats (a systemic effect) and laryngeal effects (a POE effect). While developmental effects (i.e., fetal skeletal variations) were observed in Gamer et al. (1993) , the LOAEL was much higher (202 mg/m 3 ) than that for liver effects (8.2 mg/m 3 ) and the same animal-to-human dosimetric adjustment factor would apply to both of these systemic effects. The same would be true for other systemic effects (e.g., increased relative kidney weight, changes in various red blood cell parameters) that occurred in Gamer et al. (2008) (Table 3) . Consequently, the results of Gamer et al. (1993) are not considered further for purposes of the RfC derivation other than to acknowledge that an RfC based on more sensitive effects (i.e., liver or respiratory effects) is expected to also be protective of the embryo-fetal effects observed in this study. For a straightforward apples-to-apples comparison, the LOAELs for liver effects (8.2 mg/m 3 ) and laryngeal effects (153 mg/m 3 ) were extrapolated to humans to determine the lowest LOAEL HEC and thus, the critical effect (TCEQ, 2015) . As detailed below, increased relative liver weight was ultimately determined to be the critical effect as it had the lowest LOAEL HEC (19 mg/m 3 ) of the two candidate critical effects.
While the MPPD model is typically used to extrapolate rat exposure concentrations to humans for the respiratory tract region of interest, chemicals and their effects are evaluated on a case-by-case basis (TCEQ, 2015) . In this case, while the MPPD model provides deposition fractions for the head/extrathoracic, tracheobronchial, and pulmonary regions of the respiratory tract, it does not provide larynx-specific deposition fractions, and those for the head/extrathoracic region do not appear to reflect the interspecies differences expected for the larynx based on what is reported in the literature. More specifically, the MPPD model only estimates a marginally (12%) higher deposition fraction for the rat head/extrathoracic region (0.4235) compared to the human (0.3783) at the LOAEL of 153 mg/m 3 with a midpoint MMAD of 1.25 μm and GSD of 2.5 (see Figs. 1 and 2 1 ). By contrast and for example, it is reported that interspecies differences (both anatomical and functional) between rats and humans are responsible for a reduced amount of aerosol impaction on the anterior surface of the larynx in humans compared to rodents, resulting in the rat larynx being far more sensitive than that of the non-rodent such that its response will overestimate effects relative to humans. The sensitivity of the human larynx to inhaled toxicants is more similar to that of the monkey and dog, which rarely develop laryngeal lesions in inhalation studies (Kaufmann et al., 2009; Mowat et al., 2017) . Nevertheless, using the head/extrathoracic region deposition fractions with the mean body weight (BW) of 324.5 g (male/ female combined) for the 153 mg/m 3 exposure group (Table 2 of Gamer et al., 2008) to estimate rat minute volume (Table 4-1 of USEPA, 1988) would result in the following regional deposited dose ratio (RDDR) estimate: ). Thus, increased relative liver weight in female rats is clearly the critical adverse effect for derivation of an RfC, especially considering that a more predictive RDDR specific to the larynx as the region of interest would be expected to result in a higher LOAEL HEC for laryngeal effects than that calculated here. The identification of a liver effect as the critical effect is consistent with the liver being identified as a target organ following both short-and long-term oral and dermal exposure (e.g., NTP, 1992 NTP, , 1999 ) and use of increased liver weight as a general indicator of hepatotoxicity and critical endpoint to derive numerous toxicity factors (e.g., minimal risk levels for acenaphthene, fluoranthene, fluorene, alpha-HCH, hexachloroethane, vinyl chloride, 1,4-dichlorobenzene, 1,2,3-trichloropropane, and trans-1,2-dichloroethene to name a few; ATSDR, 2005).
BMD modelling and duration adjustment
With the critical effect being identified (increased relative liver 1 The default minute ventilation (V E ) used by MPPD for humans (7500 mL/min) does not correspond to the default value (13,800 mL/min) given by USEPA (1994), which is used in the RDDR calculation. Neither USEPA (1994) nor cited USEPA background documents provide the human tidal volume (mL/breath) and breathing frequency (breaths/minute) values which correspond to the default USEPA minute ventilation and are needed for input into the MPPD so that both the MPPD model and RDDR calculation use the same human minute ventilation. Therefore, human tidal volume and breathing frequency values from de Winter-Sorkina and Cassee (2002) were used to determine the quantitative relationship between the two and calculate the tidal volume and breathing frequency values corresponding to the default USEPA minute ventilation for input into the MPPD model run for Figs. 2 and 4 (see Appendix F of TCEQ, 2011) . Similarly, a rat tidal volume of 2.54 mL was manually input for consistency between the V E value (259.0 mL/min; USEPA, 1988) identified for rats of similar weight to those in the relevant key study exposure group for laryngeal effects (324.5 g male/female mean) and that calculated based on the rat breathing frequency (102 breaths/minute) in the MPPD asymmetric multiple-path model (see Fig. 1 ), and a rat tidal volume of 1.51 mL was manually input for consistency between the V E value (154.0 mL/min) identified for rats of the same weight as those in the relevant key study exposure group for liver effects (219 g female mean) and that calculated based on rat breathing frequency in the MPPD asymmetric multiple-path model (see Fig. 3 ). These values (mL tidal volume/kg body weight) are within the range reported for Wistar rats (Filho et al., 2014) .
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Regulatory Toxicology and Pharmacology 92 (2018) 55-66 weight), BMD modelling was used to derive the POD for RfC derivation. Similar to USEPA (2012), Gamer et al. (2008) Study 2 (low exposure concentration) relative liver weight data for female rats from Table 2 were modelled using USEPA BMD software (version 2.6) to fit the data to a continuous dose-response model and calculate the BMD corresponding to a 10% increase in relative liver weight (BMD 10 ). A 10% change in organ weight relative to the control animals is often considered biologically significant. The 95% lower confidence limit on the BMD 10 was also calculated (BMDL 10 ). Goodness-of-fit for BMD modelling results was evaluated by p-values > 0.1, visual inspection of the dose-response curves relative to data points, and scaled residuals less than an absolute value of 2. As in USEPA (2012), the Power model (with nonhomogeneous variance) provided the best fit to the data and lowest Akaike's Information Criterion (AIC) value (see Fig. 5 ; modelspecific data not shown). The BMD 10 for increased relative liver weight in female rats is 7.8 mg/m 3 with a BMDL 10 of 5.5 mg/m 3 . This BMDL 10
was used for derivation of the RfC. For comparison, the BMD corresponding to 1 standard deviation (BMD 1SD ) above the control mean is also 7.8 mg/m 3 with a similar BMDL 1SD of 5.2 mg/m 3 . The corresponding BMDL 10-HEC for liver effects is 12.9 mg/m 3 (i.e., BMDL 10 of 5.5 mg/m 3 × RDDR of 2.347 = BMDL 10-HEC of 12.9 mg/m 3 ), which serves as the POD HEC for RfC derivation. Gamer et al. (2008) exposed animals for 6 h/day, 5 days/week over a period of 99 days. The exposure scenario of interest for an RfC is 24 h/ day, 7 days/week. To account for this, the POD HEC was adjusted from a discontinuous exposure regimen to continuous exposure as follows: J.T. Haney et al. Regulatory Toxicology and Pharmacology 92 (2018) 55-66 6. Derivation of the RfC TCEQ guidance (TCEQ, 2015) incorporates and is consistent with standard methods used by other agencies (e.g., USEPA) for toxicity factor development. For chronic non-carcinogenic effects, this generally entails first identifying/deriving the POD HEC-ADJ for the critical adverse effect, and then dividing it by appropriate safety factors that consider relevant areas of uncertainty (e.g., intrahuman variability, potential interspecies differences in toxicodynamics, database limitations). Accordingly, the POD HEC-ADJ of 2.3 mg/m 3 based on the critical effect of increased relative liver weight in female rats observed in Gamer et al. (2008) was divided by the following uncertainty factors:
• A full intrahuman uncertainty factor (UF H ) of 10 was used to account for potential variation in sensitivity among members of the general population (e.g., children, those with pre-existing medical conditions).
• An animal-to-human uncertainty factor (UF A ) of 3 was used to account for potential interspecies toxicodynamic differences since a dosimetric adjustment for toxicokinetic differences (i.e., using the RDDR) has already been conducted.
• A subchronic uncertainty factor (UF Sub ) of 1 was used for multiple reasons. These reasons include the observation that dose-dependent increases in rodent liver weight and relative liver weight occur for oral DEA exposure durations as short as 2 weeks (B6C3F 1 mice) with all exposure groups achieving statistically increased liver weight and relative liver weight by week 13 (NTP, 1992) . In addition, liver cytologic alterations were already present in essentially 100% of the B6C3F 1 mice in all oral exposure groups by week 13 with a high incidence of hepatocellular necrosis in 3/5 exposure groups. Statistically increased relative liver weight also occurred by week 13 in all exposure groups of F344/N rats dermally exposed to DEA and in all exposure groups of female B6C3F 1 mice (most sensitive sex) exposed dermally for 13 weeks (NTP, 1992) . These data suggest that J.T. Haney et al. Regulatory Toxicology and Pharmacology 92 (2018) actually somewhat lower than that in controls, as opposed to trending upward. That is, there is an absence of any suggestion of an increase in relative liver weight at the NOAEL that with a somewhat longer chronic duration could progress to ultimately achieve the statistically significant increase of greater than 10% necessary for a lower study relative liver weight LOAEL. Accordingly, a value of 1 is justified as it is unlikely that any progression would change the LOAEL or POD for relative liver weight identified in this study and thus result in a lower RfC. To further support this point, the 13-week LOAEL for increased relative liver weight in dermally-exposed male mice did not change as a result of two-year exposure (NTP, 1992 (NTP, , 1999 . For both 13-week and two-year exposure, the lowest dermal dose to induce statistically significant increases in relative liver weight in males was 160 mg/kg and no lower (i.e., not 40 or 80 mg/ kg). Lastly, we note that a 99-day study (Gamer et al., 2008) meets the definition of a chronic study under our guidelines (i.e., repeated exposure over a duration longer than 3 months) (TCEQ, 2015).
• A reduced database uncertainty factor (UF D ) of 3 was used because a well-conducted (e.g., OECD, EU, USEPA, GLP compliant) subchronic animal study (technically meeting the definition of a chronic study under TCEQ, 2015) evaluating a wide range of endpoints (i.e., POE, systemic) was utilized for RfC derivation and is supported by results from other studies (e.g., Gamer et al., 1996) , including Gamer et al. (1993) that evaluated developmental/reproductive endpoints. As mentioned in USEPA (2012), there are six subchronic DEA inhalation studies in three animal models (i.e., rats, dogs, guinea pigs). Although four were unpublished Eastman Kodak studies reviewed by USEPA (2012) and assessed various POE effects (e.g., gross pathology of the trachea and lungs, lung histopathology), USEPA indicated significant data reporting deficiencies (see USEPA, 2012 for additional information). The remaining subchronic studies (i.e., Gamer et al., 1996 Gamer et al., , 2008 ) evaluated numerous POE and systemic effects. Gamer et al. (1993) found no reproductive effects in inhalation-exposed female rats (e.g., conception rate or number of corpora lutea, implantation sites, pre-and post-implantation losses, resorptions, or the viability of fetuses), although a two-generation inhalation reproductive study in both sexes is lacking. Subchronic oral and dermal studies in two species (e.g., NTP, 1992) supplement the database and have also identified the liver as a sensitive target organ (e.g., see the UF Sub section above), consistent with our critical effect. For example, in a two-year dermal study (NTP, 1999) , liver weights were significantly increased in all dose groups of the more sensitive female mice with the liver reported to clearly be the most neoplastically-responsive site (female mice being more sensitive than males), further supporting the toxicological sensitivity of the liver regardless of exposure route. In regard to potential reproductive effects, while the oral DEA NTP (1992) rat and mouse study reported no such effects in female animals, the study found effects on the reproductive system in male F344/N rats (i.e., decreased testis and epididymis weights, degeneration of seminiferous epithelium, decreased spermatogenic cells) administered 630 ppm DEA in drinking water (48 mg/kg-day) for 13 weeks but not at 320 ppm (25 mg/kg-day). Using route-to-route extrapolation, this LOAEL and NOAEL equate to 81 mg/m 3 and 45 mg/m 3 , respectively [i.e., 48 mg/kg-day × 0.322 kg ( Gamer et al. (2008) is expected to be protective of potential developmental/reproductive effects in addition to other adverse effects. Confidence in the database is considered medium, Fig. 5 . BMD modelling of female rat relative liver weight data from the Gamer et al. (2008) low-concentration study.
Regulatory Toxicology and Pharmacology 92 (2018) [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] and an associated UF D of 3 is consistent with TCEQ guidelines (TCEQ, 2015 
Discussion
An inhalation RfC (25 μg/m 3 ) has been derived based on the critical effect of increased relative liver weight in female rats in the key study of Gamer et al. (2008) . More specifically, following identification of the key study through a scientific literature review, our critical evaluation of Gamer et al. (2008) At the same time, we identified a higher LOAEL for respiratory effects based on our careful evaluation of the adversity (or lack thereof) of laryngeal squamous metaplasia and other endpoint data from Gamer et al. (2008) . This determination was based on the scientific literature (e.g., Kaufmann et al., 2009; Osimitz et al., 2007; Mowat et al., 2017; Tepper et al., 2016; Stell et al., 1982a,b) and various toxicological considerations including the potential for laryngeal dysfunction, interspecies differences in laryngeal deposition, and absence of significant clinical effects. A critical evaluation of the nature of laryngeal squamous metaplasia and concomitant effects at various exposure levels resulted in considering 153 mg/m 3 to be the LOAEL for laryngeal effects in the Gamer et al. (2008) study, based primarily on laryngeal squamous hyperplasia and chronic inflammation. This is in contrast to the evaluation of effects by Gamer et al. (2008) themselves, which led them to consider the co-occurrence of laryngeal squamous metaplasia with a slight increase in inflammatory cell infiltration at 8.2 mg/m 3 to be adverse. However, like the minimal squamous metaplasia observed at lower exposure levels (see Figs. 8 and 9 of Gamer et al., 2008) , a slight increase in inflammatory cell infiltration over controls is not adverse itself, and the co-occurrence of LOELs for two non-adverse effects should not be considered to result in adversity (i.e., a LOAEL) without further critical consideration (see Section 3.1.3). In recognition of the different interspecies extrapolation methods for POE and systemic effects, the respiratory effects at their LOAEL (153 mg/m 3 ) were still considered potential critical effects, although increased relative liver weight in female rats was ultimately identified as the critical effect for RfC derivation based on a lower LOAEL HEC (TCEQ, 2015) .
Uncertainties are an inherent part of dose-response assessment and deriving toxicity factors such as an RfC. Use and extrapolation of experimental animal data to assess the potential for adverse health effects in humans yields uncertainty. The primary areas of uncertainty in this case are those typically associated with regulatory dose-response assessment and derivation of toxicity factors based on laboratory animal data (e.g., potential interspecies differences in toxicodynamics, potential intraspecies differences within the human population, database limitations). In recognition of these uncertainties, UFs were applied to the POD HEC-ADJ in deriving the RfC, including a UF for intrahuman variability in susceptibility (i.e., a full UF H of 10 along with a UF A of 3 and UF D of 3). The UF values selected by other agencies may differ somewhat based on their own considerations, guidance, and scientific judgment (e.g., UF Sub ). Regardless, it is recognized that the overall methodology is designed to be sufficiently conservative in recognition of the uncertainties associated with deriving toxicity factors.
Based on our evaluation of the most sensitive adverse effects, an RfC of 25 μg/m 3 is considered health protective for the general population.
Under TCEQ guidelines (TCEQ, 2015) , this toxicity factor is termed a chronic ReV. While chronic ReVs can be used to evaluate the potential human health effects of long-term (≥1 year) environmental exposure of the general public to the chemical (i.e., long-term, ambient air groundlevel dispersion modelling results or monitoring data), for air permitting purposes the TCEQ multiples ReVs by a factor of 0.3 (considering cumulative and aggregate exposure) to derive an effects screening level (ESL). Thus, the chronic ESL corresponding to the calculated chronic RfC/ReV would be 7.5 μg/m 3 .
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